A new device for the injection of tralokinumab is one step closer to approval in European Union member states. The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines ...
The human monoclonal antibody known as tralokinumab-ldrm was tested and approved as a safe, effective treatment for pediatric patients with atopic dermatitis aged 12 to 17 years old. Originally ...
LEO Pharma A/S, a global leader in medical dermatology, today announced the presentation of new post-hoc analyses of 12‑month real‑world data from the TRACE study of tralokinumab, at the 2026 American ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results